The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study by Shiffman, Dov et al.
RESEARCH ARTICLE Open Access
The contribution of a 9p21.3 variant, a KIF6
variant, and C-reactive protein to predicting risk
of myocardial infarction in a prospective study
Dov Shiffman
1*, Ellen S O’Meara
2, Charles M Rowland
1, Judy Z Louie
1, Mary Cushman
3, Russell P Tracy
4,
James J Devlin
1, Bruce M Psaty
5
Abstract
Background: Genetic risk factors might improve prediction of coronary events. Several variants at chromosome
9p21.3 have been widely reported to be associated with coronary heart disease (CHD) in prospective and case-
control studies. A variant of KIF6 (719Arg) has also been reported to be associated with increased risk of CHD in
large prospective studies, but not in case-control studies. We asked whether the addition of genetic information
(the 9p21.3 or KIF6 variants) or a well-established non-genetic risk factor (C-reactive protein [CRP]) can improve risk
prediction by the Framingham Risk Score (FRS) in the Cardiovascular Health Study (CHS)–a prospective
observational study of risk factors for cardiovascular disease among > 5,000 participants aged 65 or older.
Methods: Improvement of risk prediction was assessed by change in the area under the receiver-operator
characteristic curve (AUC) and by net reclassification improvement (NRI).
Results: Among white participants the FRS was improved by addition of KIF6 719Arg carrier status among men as
assessed by the AUC (from 0.581 to 0.596, P = 0.03) but not by NRI (NRI = 0.027, P = 0.32). Adding both CRP and
719Arg carrier status to the FRS improved risk prediction by the AUC (0.608, P = 0.02) and NRI (0.093, P = 0.008) in
men, but not women (P ≥ 0.24).
Conclusions: While none of these risk markers individually or in combination improved risk prediction among
women, a combination of KIF6 719Arg carrier status and CRP levels modestly improved risk prediction among
white men; although this improvement is not significant after multiple-testing correction. These observations
should be investigated in other prospective studies.
Background
The Framingham Risk Score (FRS) is a risk prediction
model developed by the Framingham investigators to
predict the probability of developing coronary heart dis-
ease (CHD) [1]. This risk prediction model calculates
the probability of a CHD event over a given time period
for men and women separately by integrating informa-
tion about traditional risk factors for CHD, including
age, blood pressure, low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C),
smoking behavior, and diabetes status. The FRS has
been evaluated in a number of large population studies
and has been shown to predict CHD risk among indivi-
duals from different populations and a variety of ethnici-
ties [2]. Because the FRS models were developed as
sex-specific scores, the validity of FRS was typically eval-
uated separately in men and women [2].
Several groups have sought to improve or simplify
CHD risk prediction by the FRS [3-6] by developing
models that include emerging risk factors. More
recently, several studies have investigated whether
genetic variants associated with CHD could improve
CHD risk prediction models, and much attention has
been focused on a well-established genetic risk marker
in the 9p21.3 locus (see Palomaki et al. [7] for a recent
meta analysis). The results of these studies have been
mixed. One study found that adding 9p21.3 to a
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under the receiver operator characteristic curve (AUC)
as well as patient reclassification [8]. A second study
f o u n di m p r o v e m e n ti nr e c l a s s i f i c a t i o n ,b u tn o ti nA U C
[9]. And a third study found that 9p21.3 did not
improve either AUC or patient reclassification [10].
Another gene variant associated with risk of CHD is a
nonsynonymous (Trp719Arg) single nucleotide poly-
morphism in KIF6, which encodes a member of the
kinesin superfamily. This KIF6 variant (rs20455) was
associated with increased risk of CHD in the placebo
groups of randomized placebo-controlled clinical trials:
the secondary prevention Cholesterol and Recurrent
Events (CARE) study and the primary prevention West
of Scotland Coronary Prevention Study (WOSCOPS)
[11]. This KIF6 variant was also associated with CHD in
prospective population-based studies: Atherosclerosis
Risk in Communities (ARIC) study [12], Cardiovascular
Health Study [13], and the Women’s Health Study [14].
Interestingly, the KIF6 v a r i a n tw a sn o ta s s o c i a t e dw i t h
risk of coronary artery disease in case-control studies
[15,16], the explanation for the difference between the
results from the prospective studies and the case control
studies remains to be determined.
It has been suggested that the genetic contribution to
CHD risk diminishes with age [17]. Since the contribu-
tion of genetic markers to CHD risk models has typi-
cally been assessed in prospective studies of middle-aged
individuals, we set out to assess the contribution of
genetic markers to CHD risk models in the Cardiovas-
cular Health Study (CHS), a prospective study among
Americans aged 65 or older who were followed for the
occurrence of cardiovascular events [18]. Since the FRS
predicts CHD risk in this population [2], CHS provided
the opportunity to ask whether genetic risk markers can
improve CHD risk prediction by the FRS among older
North Americans. As a point of reference, we also inves-
tigated whether C-reactive protein (CRP)–aw e l le s t a b -
lished [19] non-genetic risk marker–can improve CHD
risk prediction in the same population. Therefore, we
report here the contribution of 9p21.3, KIF6 719Arg and
CRP to CHD risk prediction in CHS.
Methods
Cardiovascular Health Study
CHS is a prospective observational study of risk factors
for cardiovascular disease in older adults. The recruit-
ment and design methods were previously described
[18,20]. Briefly, men and women aged 65 years and older
were recruited from random samples of Medicare elig-
ibility lists in 4 US communities (Sacramento County,
CA; Washington County, MD; Forsyth County, NC; and
Pittsburgh, PA) and from age-eligible participants in the
same household. Potential participants were excluded if
they were institutionalized, not ambulatory at home,
under hospice care, receiving radiation or chemotherapy
for cancer, not expected to remain in the area for at least
3 years, or unable to be interviewed. CHS enrolled 5201
participants from 1989 to 1990; an additional 687 African
American participants entered the cohort from 1992 to
1993. The CHS cohort of 5888 was 57.6% female and
15.7% African American. The mean age at enrollment
was 72.8 years (standard deviation 5.6). The institutional
review board at each site approved the study methods,
and all participants gave written informed consent. Col-
lection of baseline demographic, clinical, and genetic data
was previously described [13,18,21,22]. Briefly, partici-
pants completed a baseline clinic examination [18] that
included a medical history interview, physical examina-
tion, and blood draw[21]. Baseline self-reports of MI or
stroke were confirmed by information from the clinic
examination or by review of medical records or physician
questionnaires [22]. Genotypes of the CHS participants
were determined using a multiplex method that com-
bines polymerase chain reaction (PCR), allele-specific oli-
gonucleotide ligation assays, and hybridization to
oligonucleotides coupled to Luminex 100TM ×MAP
microspheres (Luminex, Austin, TX) as previously
described [13]. Cardiovascular events during follow-up
were identified at semiannual contacts, which alternated
between clinic visits and telephone calls. Suspected
events were adjudicated according to standard criteria by
a physician review panel using information from medical
records and, in some cases, interviews with the physician,
participant, or a proxy informant [23]. Medicare utiliza-
tion files were searched to ascertain events that may have
been missed. In this analysis, MI was defined as definite
or probable nonfatal MI or definite fatal MI.
Statistical analysis
Participants with unavailable DNA or who did not con-
sent to the use of their DNA for studies by private com-
panies (N = 514) were excluded from the present study.
Participants for whom DNA samples were inadequate
(N = 130) were also excluded. Analyses also excluded
participants who had a baseline history of MI (N = 517
of the 5244 participants), or stroke (N = 222), who were
neither white nor African American (N = 30), or who
had missing data for calculating the FRS or the three
risk markers (n = 284). After applying these overlapping
exclusions, 4284 participants remained for analysis.
We conducted analyses of time to incident MI. Fol-
low-up began at CHS enrollment and ended on the date
of incident MI, death, loss to follow-up, or June 30,
2006, whichever occurred first. The median time at risk
was 12.6 years. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were estimated using Cox regression
models. Based on their use in the FRS, variables were
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status, hypertension, LDL-C category, HDL-C category,
diabetes, KIF6 719Arg carrier status), or ordinal (9p21.3
SNP: rs10757274).
The predicted 10-year risk of incident MI for each
participant in this study was calculated based on esti-
mates of the baseline hazard function and the regression
coefficients of Cox models that included the FRS vari-
ables with or without additional risk markers as
described [1]. These analyses were conducted in men
and women separately as described [1,2]. The risk mar-
kers that were added to the FRS were coded continu-
ously (CRP), additively (9p21.3 SNP), or dominantly
(KIF6 719Arg) because this coding was consistent with
what was reported previously for these risk markers.
The change in the AUC was used to assess the improve-
ment of the FRS by additional risk markers.
To assess whether adding risk markers to FRS resulted
in reclassification of individuals to more appropriate risk
categories, we used the net reclassification improvement
(NRI) measure [24]. Briefly, among those with incident
events, classification is more appropriate if the indivi-
dual is reclassified to a higher risk category and less
appropriate if the individual is reclassified to a lower
risk category. For those without incident events, the
converse is true. The difference in the proportion of
individuals moving to more appropriate and less appro-
priate categories is calculated separately for those with
and without incident events. The NRI is the sum of
these two differences. The predicted CHD probabilities
were grouped into 10-year risk categories of 0% to < 5%,
5% to < 10%, 10% to < 20%, and 20% or greater based
on FRS models with and without additional risk mar-
kers. Statistical tests were two-sided. Data were analyzed
using Stata statistical software [25].
Results
The baseline characteristics that were used to calculate the
FRS among the 3651 white participants in this analysis are
presented in Table 1, which also presents coefficients from
Table 1 Framingham Risk Score Characteristics at Baseline Among White Participants
Men n = 1495 Women n = 2156
Baseline Value b (P value)* Baseline Value b (P value)*
Age, y, mean (SD) 73.3 (5.7) 0.043 (0.0002) 72.3 (5.4) 0.18 (0.45)
Current smoker 10% -0.19 (0.44) 12% 0.49 (0.01)
LDL, mg/dL, mean (SD) 124 (33) NA§ 135 (37) NA§
LDL category
< 100 24.4% -0.13 (0.45) 16.8% -0.18 (0.38)
100-129 35.0% reference 30.7% reference
130-159 28.0% 0.10 (0.49) 29.4% -0.04 (0.80)
160-189 10.0% 0.22 (0.29) 16.2% 0.10 (0.57)
> = 190 2.7% -0.19 (0.65) 6.9% -0.23 (0.41)
HDL, mg/dL, mean (SD) 48 (13) NA§ 59 (16) NA§
HDL category
< 35 11.4% 0.16 (0.47) 1.9% -0.24 (0.65)
35-44 34.1% 0.090 (0.60) 14.2% 0.15 (0.43)
45-49 18.3% reference 13.0% 0.20 (0.30)
50-59 20.5% -0.21 (0.29) 26.9% reference
> = 60 15.6% -0.030 (0.89) 43.9% -0.18 (0.27)
Blood pressure category†
Optimal 23.3% -0.31 (0.14) 23.8% 0.22 (0.34)
Normal 18.5% reference 18.0% reference
high normal 20.2% 0.30 (0.13) 19.2% 0.46 (0.05)
HTN stage I 23.8% 0.39 (0.04) 26.2% 0.58 (0.007)
HTN stage II-IV 14.1% 0.21 (0.33) 12.8% 0.95 ( 0.00005)
Diabetes‡ 13.0% 0.57 (0.0006) 8% 0.66 (0.001)
*Coefficients from Cox regression model of Framingham Risk Score (FRS) variables.
†Optimal (systolic < 120 mm Hg and diastolic < 80 mm Hg), normal blood pressure (systolic 120 to 129 mm Hg or diastolic 80 to 84 mm Hg), high normal blood
pressure (systolic 130 to 139 mm Hg or diastolic 85 to 89 mm Hg), hypertension stage I (systolic 140 to 159 mm Hg or diastolic 90 to 99 mm Hg), and
hypertension stage II-IV (systolic 160 or diastolic 100 mm Hg). When systolic and diastolic pressures fell into different categories, the higher category was
selected. Blood pressure categorization was made without regard to the use of antihypertensive medication.
‡Fasting serum glucose ≥140 or taking insulin or oral hypoglycemic medications.
§Continuous cholesterol measures are not included in the FRS model.
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the coefficients estimated among men and women sepa-
rately because the FRS coefficients were originally derived
separately in men and women and because cardiovascular
risk is generally different between men and women–men
generally have CHD events earlier in life. The AUC among
whites was 0.581 for men and 0.619 for women. After
adjustment for the FRS risk factors, the risk allele (G) of
the 9p21.3 SNP (rs10757274) was associated with increased
risk of MI among white men (HR = 1.22; 95%CI 1.03 to
1.45, P = 0.02), this association did not reach statistical sig-
nificance among white women (HR = 1.16; 95%CI 0.98 to
1.37, P = 0.08). Carriers of one or two 719Arg alleles of
KIF6 were at increased risk of MI among white men (HR =
1.42; 95%CI 1.11 to 1.82, P = 0.006) but not women (HR =
1.05; 95%CI = 0.83 to 1.33, P = 0.68). Higher CRP was
associated with increased risk of incident MI among both
white men (HR = 1.28 for 1 standard deviation higher
CRP; 95%CI 1.14 to 1.45, P = 0.00005) and white women
(HR = 1.15; 95%CI 1.01 to 1.31, P = 0.04).
Among white participants, adding rs10757274 in the
9p21.3 locus to the FRS variables, did not improve the
AUC among either men or women (P ≥ 0.35, Tables 2
and 3). In the net reclassification improvement (NRI)
analysis, adding 9p21 to the FRS reclassified 13.7% of
white men and 10.3% of white women to risk categories
that were different from the FRS categories. However, the
net number of individuals that were classified to more
appropriate risk categories was ≤ 25, with the NRI ≤ 0.02
(P ≥ 0.39). Similar results were observed after CRP was
added to FRS. The AUC was not improved for either
white men or women (P ≥ 0.15) nor was the NRI signifi-
cant (NRI ≤ -0.01, P ≥ 0.19). The net number of correctly
reclassified individuals was ≤ 10 in each of the two sexes.
Similarly, adding KIF6 719Arg carrier status to the FRS
variables did not improve risk prediction by the NRI
among either men or women (NRI ≤ 0.027, P ≥ 0.32, the
net number of correctly reclassified individuals was ≤ 33).
However, adding KIF6 719Arg carrier status to the FRS
modestly improved the AUC among men (from 0.581 to
0.596; P = 0.03), though not among women (P = 0.57).
Since the nominal value of the AUC after addition of
an individual risk marker to the FRS was larger than the
AUC of FRS alone (Tables 2 and 3), we asked if adding
more than one marker to the FRS further improved risk
prediction. Adding all three markers to the FRS resulted
in the largest AUC among white men (0.612, P = 0.01
for difference from the FRS AUC, Figure 1) and largest
net number of correctly reclassified individuals (93, P =
0.04). However, adding all three markers to the FRS did
not improve risk prediction among white women. Add-
ing both CRP and 9p21.3 to the FRS, resulted in a mar-
ginal increase in the AUC among white men (to 0.599;
P = 0.09), but not among white women. The NRI did
not indicate improvement of risk prediction among
either white men or women (P ≥ 0.4). In contrast, addi-
tion of KIF6 with either CRP or 9p21.3 to the FRS
resulted in a larger AUC among white men (0.600 and
0.608 respectively; P ≤ 0.03) but not among women.
The combination of KIF6 and CRP also improved risk
prediction by the NRI among white men (NRI = 0.093,
P = 0.008, the net number of correctly reclassified indi-
viduals = 86) but not among women. However, the NRI
was not significant when men and women were com-
bined (NRI = 0.026, P = 0.2).
For the 228 African American men and 405 women
( T a b l e4 ) ,n o n eo ft h e3r i s k markers were associated
with incident MI (P ≥ 0.05). The power to detect asso-
ciation between the genetic risk factors and MI was <
37% to detect a risk ratio of 1.5. Thus, all results among
African Americans are reported in the online supple-
ment. Among African American participants of CHS,
only 9p21.3 improved risk prediction among men as
assessed by NRI (NRI = 0.182; P = 0.02, net number of
correctly reclassified individuals = 10). None of the
other markers individually or in combination improved
risk prediction by the FRS (Tables 5 and 6).
Discussion
We investigated whether adding a 9p21.3 variant, a KIF6
variant, or CRP to the FRS could improve MI risk pre-
diction in CHS, a large prospective study of individuals
Table 2 Addition of Risk Markers to the FRS: Effect on Risk Prediction in White Men
Markers Added
to FRS Model
Number Reclassified (%) Net Number Reclassified
Correctly (NRI, P value)
AUC (P value)*
9p21.3 205 (13.7) 25 (0.021, 0.41) 0.586 (0.35)
KIF6 309 (20.7) 33 (0.027, 0.32) 0.596 (0.03)
CRP 346 (23.1) 10 (-0.017, 0.61) 0.595 (0.15)
CRP + 9p21.3 412 (27.6) 56 (0.029, 0.40) 0.599 (0.09)
CRP + KIF6 466 (31.2) 86 (0.093, 0.008) 0.608 (0.02)
9p21.3 + KIF6 348 (23.3) 40 (0.041, 0.18) 0.600 (0.03)
CRP + 9p21.3 + KIF6 495 (33.1) 93 (0.076, 0.04) 0.612 (0.01)
*P value for change in the AUC from the AUC of the FRS model (0.581).
Shiffman et al. BMC Cardiovascular Disorders 2011, 11:10
http://www.biomedcentral.com/1471-2261/11/10
Page 4 of 8aged 65 years or older from American communities.
Adding individual risk markers had, at best, a modest
effect on risk prediction. Adding two or more risk mar-
kers, specifically risk marker combinations that included
the KIF6 719Arg genotype, resulted in a somewhat
higher, though still modest improvement in risk predic-
tion as measured among white males by either the AUC
or by NRI, but not in the combined male and female
population.
The appropriate methods for assessing improvement
of risk prediction by risk markers have been widely
debated [26]. And given the limitations of the AUC
measure, alternative assessment methods such as NRI
have been proposed [24]. Although the current study
was not designed to compare the AUC and NRI, the
results from these two measures were largely consistent.
The ability of CRP to improve risk stratification has
been evaluated in multiple studies, which found that the
addition of CRP to risk prediction models provided
modest improvement in risk prediction (see Buckley
et al. [19] and Schnell-Inderst et al. [27] for recent
comprehensive evaluations). In CHS, CRP did not
improve risk prediction by the FRS as assessed by the
AUC or NRI measures, consistent with previously pub-
lished observations that the association of a risk factor
with MI after adjustment for the FRS variables does not
necessarily mean that the risk factor will improve risk
prediction beyond the FRS, as measured by the change
i nt h eA U C ,p a r t l yb e c a u s ee v e nr i s kf a c t o r sw i t hl a r g e
odds ratio (up to 7) have distributions that overlap sub-
stantially between those with and without disease
[28,29]. However, the addition of CRP in combination
with KIF6 719Arg to the FRS improved risk prediction
by both the AUC and NRI measures among white men.
Although the association between CHD and SNPs in
the 9p21.3 locus has been reported extensively [7], Deh-
ghan et al. [30] reported that SNPs in this locus were
not associated with risk of CHD in a prospective study
of older Europeans. In contrast, we have observed in
CHS, a population of individuals 65 years and older,
that a SNP in the 9p21.3 locus is associated with MI
among men, although this association did not reach sta-
tistical significance among women. We have also
observed in CHS an association between MI and KIF6
719Arg carrier status among men but not among
women. However, published results from the Women’s
Health Study [10,14] suggest that both 9p21.3 and KIF6
719Arg are associated with MI among women. These
inconsistent findings among women could be due to
lack of power in CHS, or to different baseline risk of MI
in CHS and the Women’s Health Study. Additional ana-
lysis of the 9p21.3 and KIF6 variants in prospective stu-
dies of women would be required to understand this
apparent inconsistency.
The addition of the 9p21.3 variant to the FRS did not
improve risk prediction in CHS as measured by either the
AUC or NRI among whites. Similarly, addition of a SNP in
the 9p21.3 locus did not improve risk prediction by tradi-
tional risk factors in the Women’s Health Study [10]. How-
ever, in ARIC [8] the addition of 9p21.3 to the FRS
resulted in a modest but statistically significant improve-
ment in risk prediction as measured by AUC or
Table 3 Addition of Risk Markers to the FRS: Effect on Risk Prediction in White Women
Markers Added to FRS Model Number Reclassified (%) Net Number Reclassified
Correctly (NRI, P value)
AUC (P value)*
9p21.3 222 (10.3) -16 (-0.018, 0.39) 0.621 (0.57)
KIF6 72 (3.3) 0 (0.007, 0.61) 0.618 (0.57)
CRP 270 (12.5) -10 (-0.032, 0.19) 0.617 (0.69)
CRP + 9p21.3 362 (16.8) 20 (0.007, 0.81) 0.620 (0.81)
CRP + KIF6 276 (12.8) -4 (-0.029, 0.24) 0.617 (0.67)
9p21.3 + KIF6 246 (11.4) -2 (0.015, 0.52) 0.620 (0.65)
CRP + 9p21.3 + KIF6 357 (16.6) 3 (-0.002, 0.95) 0.620 (0.81)
*P value for change in the AUC from the AUC of the FRS model (0.619).
Figure 1 Risk Prediction among White Men in the
Cardiovascular Health Study. Receiver operator characteristic
curves calculated for the white men participants of CHS. Blue:
Framingham risk score. Red: KIF6, 9p21.3, and CRP added to the
Framingham risk score.
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[9] adding 9p21.3 improved reclassification but not AUC.
These inconsistent results could be attributed to differences
in baseline risk between the studies, (the older CHS popu-
lation is likely to have greater baseline risk of MI), which
could affect the power to detect the modest improvement
in risk prediction contributed by the 9p21.3 variant.
Genetic and non-genetic biomarkers offer different
benefits in the assessment of CHD risk. Non-genetic
biomarkers could change over time, and therefore,
repeat measurements may be necessary because of day-
to-day variation in the level of these biomarkers. How-
ever, repeat measurements of non-genetic biomarkers
may also provide an indication of successful medical
Table 4 Framingham Risk Score Characteristics at Baseline among Black Participants
Men n = 228 Women n = 405
Baseline Value b (P value)* Baseline Value b (P value)*
Age, y, mean (SD) 72.3 (5.5) 0.035 (0.33) 73.0 (5.6) 1.37 (0.05)
Current smoker 23% 0.28 (0.55) 14% 0.0085 (0.99)
LDL, mg/dL, mean (SD) 124 (32) NA§ 132 (37) NA§
LDL category
< 100 22.4% 0.36 (0.46) 17.8% 1.08 (0.02)
100-129 34.2% reference 33.3% reference
130-159 31.6% -0.34 (0.51) 29.4% 0.67 (0.13)
160-189 9.6% 0.92 (0.11) 12.6% 0.52 (0.33)
> = 190 2.2% 0.066 (0.95) 6.9% 1.20 (0.02)
HDL, mg/dL, mean (SD) 53 (14) 61 (15)
HDL category
< 35 4.4% -0.22 (0.84) 0.7%
35-44 23.2% -0.75 (0.15) 11.85 -0.43 (0.45)
45-49 21.5% reference 9.9% -0.18 (0.76)
50-59 24.1% -1.06 (0.05) 29.9% reference
> = 60 26.8% -0.69 (0.16) 47.6% -0.17 (0.64)
Blood pressure category†
Optimal 17.1% -0.46 (0.52) 13.6% 0.59 (0.50)
Normal 17.5% reference 14.1% reference
high normal 19.3% 0.080 (0.89) 18.0% 0.81 (0.32)
HTN stage I 32.0% 0.34 (0.52) 31.1% 1.01 (0.18)
HTN stage II-IV 14.0% 0.67 (0.29) 23.2% 1.55 (0.04)
Diabetes‡ 19% -0.15 (0.76) 20% 0.51 (0.17)
*Coefficients from Cox regression model of Framingham Risk Score (FRS) variables.
†Optimal (systolic < 120 mm Hg and diastolic < 80 mm Hg), normal blood pressure (systolic 120 to 129 mm Hg or diastolic 80 to 84 mm Hg), high normal blood
pressure (systolic 130 to 139 mm Hg or diastolic 85 to 89 mm Hg), hypertension stage I (systolic 140 to 159 mm Hg or diastolic 90 to 99 mm Hg), and
hypertension stage II-IV (systolic 160 or diastolic 100 mm Hg). When systolic and diastolic pressures fell into different categories, the higher category was
selected. Blood pressure categorization was made without regard to the use of antihypertensive medication.
‡Fasting serum glucose ≥140 or taking insulin or oral hypoglycemic medications.
§Continuous cholesterol measures are not included in the FRS model.
Table 5 Addition of Risk Markers to the FRS: Effect on Risk Prediction in Black Men
Markers Added
to FRS Model
Number Reclassified (%) Net Number Reclassified
Correctly (NRI, P value)
AUC (P value)*
9p21 50 (21.9) 10 (0.182, 0.02) 0.688 (0.07)
KIF6 no data† no data† no data†
CRP 48 (21.1) -4 (0.006, 0.94) 0.654 (0.92)
CRP + 9p21 70 (30.7) 10 (0.129, 0.16) 0.675 (0.51)
CRP + KIF6 no data† no data† no data†
9p21 + KIF6 no data† no data† no data†
CRP + 9p21 + KIF6 no data† no data† no data†
*P value for change in AUC from AUC of the FRS model (0.657).
†Risk for KIF6 cannot be calculated because none of the 15 African American men who were noncarriers of the KIF6 719Arg risk allele had an event.
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not change and thus need only be measured once to
obtain information about the lifelong exposure to that
biomarker. The 9p21.3 and KIF6 gene variants were
chosen for investigation because they have both been
reported to be associated with CHD in multiple pro-
spective studies and are common variants. For example,
in the white population about 75% of carry at least one
risk allele of 9p21.3 and about 65% carry at least one
KIF6 719Arg risk allele. CRP was chosen because of the
well-established association between CRP levels and risk
of CHD and because of continuing interest in whether it
should be added to risk prediction algorithms. Elevated
CRP is also common. For example, although CRP was
analyzed as a continuous variable in this study in order
to increase the power of the study, others have reported
that in CHS, 26% of the population have elevated CRP
(> 3 mg/dL) [31]. Thus, ~17% of the CHS white popula-
tion have both elevated CRP and carry the 719Arg allele
of KIF6.
This study has several limitations. The AUC of the
FRS model for white men (0.581) and white women
(0.619) in this study of older individuals is lower than
the AUC that has been reported for middle age popula-
tions (e.g., 0.75 and 0.83 among white men and among
white women in ARIC [2]), thus the markers we studied
may only improve risk prediction in populations in
which the ability of the FRS to predict CHD is modest.
The difference observed between the AUC and NRI
measures for the addition of KIF6 719Arg among men
could be attributed to the overall modest improvement
of risk prediction by single marker addition. Another
limitation of this study is the limited number of genetic
markers evaluated–a recent paper suggested that risk
prediction models might be improved by incorporating
large number of genetic markers into a genetic risk
score [32]. Lastly, the effect of these single and multiple
marker additions on risk prediction was investigated in
a population of individuals aged 65 or older at baseline
and our observations may not be generalizable to
younger populations.
Conclusions
In the white male population of CHS, the addition of
KIF6 719Arg in combination with 9p21.3, CRP, or both
modestly improved risk prediction. This improvement
was not significant after multiple-testing correction and
was not observed in the combined male and female
population.
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